Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib
Status:
Terminated
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if the combination of Vemurafenib with Decitabine plus
Cobimetinib improves the low therapy response rate in subjects with malignant melanoma.